[ET Net News Agency, 10 November 2021] Credit Suisse maintained its target price for
Wuxi Bio (02269) at HK$151 and maintained its "outperform" rating.
The research house said Wuxi Bio's abundant manufacturing capacity is expected to meet
increasing CMO demands. (RC)